DGAP-News: PAION AG REPORTS ON THE FINANCIAL YEAR 2014 AND

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: PAION AG REPORTS ON THE FINANCIAL YEAR 2014 AND FINANCIAL RESULTS

DGAP-News: PAION AG / Key word(s): Final Results PAION AG REPORTS ON THE FINANCIAL YEAR 2014 AND FINANCIAL RESULTS 18.03.2015 / 07:30 --------------------------------------------------------------------- PAION AG REPORTS ON THE FINANCIAL YEAR 2014 AND FINANCIAL RESULTS - Financial results in line with plan - Positive Phase II results with Remimazolam in cardiac surgery - Licensing deals for Remimazolam in the MENA region and Canada - Cash position 58.9 million EUR (resulting from successful capital measures totaling EUR 61.4 million) - US-based subsidiary PAION, Inc. established - Termination of partnership with Ono in Japan - Regulatory interactions on Phase III programs with FDA and EMA - Start in the US end of Q1 2015, EU towards end of H1 2015 - Development of Solulin and PN 13 discontinued - Conference call (in English) today at 2:00 pm CET (1:00 pm GMT/9:00 am EDT) Aachen (Germany), 18 March 2015 - Specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today reports its consolidated financial results according to International Financial Reporting Standards (IFRS) for 2014 (1 January to 31 December). In 2014, revenues amounted to EUR 3.5 million and thus were EUR 0.8 million lower compared to 2013. They mainly comprised the license agreements with Yichang Humanwell for M6G completed in 2014 (EUR 1.6 million), the license agreements with R-Pharm (EUR 1.5 million), and with Pendopharm (EUR 0.4 million). In the prior-year period, the revenues mainly resulted from the license agreements for Remimazolam of the years 2012 and 2013 for China, South-Korea, Russia/CIS and Turkey. R&D expenses increased from EUR 4.6 million in 2013 to EUR 11.8 million in 2014 due to increased development activities with Remimazolam. General administrative and selling expenses slightly increased from EUR 3.3 million 2013 to EUR 3.7 million in 2014 due to the planned increase in staff. The financial year 2014 closed with a net loss of EUR 9.1 million, thus exceeding the net loss of EUR 2.2 million of 2013 substantially but according to plan. Cash and cash equivalents increased by a total of EUR 45.6 million in 2014 due to the capital increases conducted in the fiscal year. As of 31 December 2014, PAION's cash and cash equivalents amounted to EUR 58.9 million. Thus, PAION has sufficient funds to conduct the planned Phase III programs with Remimazolam in the EU and the US including the filing process, and to initiate premarketing and market access activities. Dr. Wolfgang Söhngen, CEO of PAION AG commented: "We look back at an intensive and very positive year. Economically, the financial year clearly exceeded market expectations and we are proud that our shareholders supported us in all our capital measures. As a result, we have secured the financing for the development program and approval process for Remimazolam. We have made great progress in all aspects of the Remimazolam development and managed the intensive and time consuming process of the necessary regulatory interactions both for the US and EU programs. Positive Phase II study data in cardiac surgery enabled us to initiate pre-marketing and scientific meeting activities. With the incorporation of PAION, Inc., we created new options for the US commercialization. We continued our "String of Pearls" strategy. Unfortunately and to our surprise, the partnership with Ono was terminated but this also may lead to new chances in Asia. Our Phase III program will start shortly in the US, and in the EU we expect this to happen by the end of the first half of 2015, after we have received the final scientific advice from the EMA last week. We are looking forward to a busy year 2015." Development and commercial activities In 2014, PAION focused on the development and partnering of Remimazolam. In February 2014, only five months after the start, patient recruitment of the Phase II clinical trial with the short-acting anesthetic/sedative Remimazolam in the indication "General Anaesthesia" in patients undergoing cardiac surgery at the Heart Center Leipzig was completed and positive data were announced in May 2014. The safety profile was very good in all treatment groups. One of the key objectives of this trial was to assess the hemodynamic stability during cardiac surgery with Remimazolam when compared to Propofol/Sevoflurane. Drops in blood pressure under Propofol and Sevoflurane are often described in the literature as an undesirable anesthesia side effect. In cardiac surgery, norepinephrine is routinely employed to keep the blood pressure in the normal range and to counteract excessive blood pressure drops. However, norepinephrine and similar substances can affect the microcirculation in vital organs and lead to poor long-term outcomes including increased mortality. The reduction of norepinephrine doses is therefore of great medical relevance. Remimazolam has demonstrated less blood pressure drops and less use of norepinephrine than Propofol or the combination of Propofol and Sevoflurane during clinical trials conducted in general anesthesia in general and in cardiac surgery. In June 2014, PAION and R-Pharm, Russia, extended their license agreement concerning the exclusive rights of development and commercialization of Remimazolam to the MENA region (Middle East and North Africa). Based on this extension, PAION received a payment in the amount of EUR 1.5 million. Moreover, potential regulatory and commercial milestone payments of up to EUR 5.5 million and low double-digit royalties on net sales in the territory were agreed upon. After the completion of an exclusivity agreement with Pendopharm's European affiliate, Pharmascience International Ltd., in June 2014, the definitive license agreement for the development and commercialization of Remimazolam in the territory of Canada was signed in July 2014. Based on this license agreement, PAION is entitled to receive potential regulatory and commercial milestone payments of up to CAD 5.7 million and significant double-digit tiered royalties on net sales in Canada, starting at 15 %. A private placement in the volume of EUR 4 million at a subscription price of EUR 3.1463 followed. The 10 % premium to the share price of a total of EUR 0.4 million is disclosed as revenues. In September 2014, PAION entered into a license agreement with Yichang Humanwell for the drug candidate M6G. Accordingly, Yichang Humanwell receives the exclusive license for M6G and access to the data and know-how regarding the development, manufacturing and commercialization of M6G in China. PAION receives payments totaling EUR 1.6 million. Additional license fees were not agreed. In November 2014, Ono decided "to discontinue the project on strategic reasons considering issues in pharmacokinetic features, while no adverse events of concern were observed during clinical trials". Therefore, Ono will return its Remimazolam rights and will not file for regulatory approval. There will be no repayment for received milestone payments. Remimazolam is available for licensing in Japan to other parties. An alternative filing strategy for Remimazolam in Japan in the indication of general anesthesia through PAION or another partner is currently being evaluated. Several companies have expressed their interest in a Remimazolam license for Japan. In October 2014, the Phase II trial results in anesthesia were presented at "The Anesthesiology 2014 Annual Meeting" (ASA) in New Orleans, USA, and the colonoscopy Phase IIb trial results in procedural sedation were presented at the "American College of Gastroenterology Annual Scientific Meeting" (ACG) in Philadelphia, USA, by the investigators. Remimazolam raised a lot of interest. As part of pre-marketing activities, PAION performed primary market research on site. The differentiation of Remimazolam to the generic substances Midazolam and Propofol was confirmed by the specialists as a necessary innovation in the field of anesthesia and procedural sedation. In order to increase its presence in the North American market, PAION has established a US subsidiary, PAION, Inc. in October 2014. The company is located in New Jersey and being run by Greg Papaz, CEO of PAION, Inc. The US subsidiary is responsible for the positioning of Remimazolam in the United States. This includes support of the US Phase III program for procedural sedation. In addition, PAION, Inc. will implement the strategic plan for market access and commercialization of Remimazolam in the US. This enables PAION to explore the option of a "Go It Alone Strategy" in the US. In November 2013, PAION had a positive End-of-Phase II Meeting with the FDA. Since that time, the dialogue continued throughout 2014 to define all the details and approval requirements for Remimazolam in the indication "procedural sedation". During this time, the agency commented on the study protocols and other aspects of the rest of the development program such as the production of the substance and some accompanying preclinical and Phase I protocols. As a result of a comprehensive coordination process and the feedback received in several steps from the FDA, the Phase III study protocols were submitted to the FDA in November 2014. End of February 2015, PAION received feedback from the FDA. PAION has adjusted the study protocols according to the FDA's recommendations and resubmitted the changes to the IRB (Ethic Committee). The study start is scheduled for end of March 2015. The interactions with the European Medicines Agency (EMA) for the EU lead indication "anesthesia" were constructive and the development program until filing for market approval was discussed. Based on the scientific advice, the study protocols are now being completed and submitted to the national agencies and IRBs. PAION expects to initiate the trial towards the end of the first half of 2015. Due to the focus of the available resources on anesthesia, Solulin and PN 13 could only have been continued with third party funding. So far, no funding partners could be identified, which is why PAION decided to discontinue the further development of Solulin and PN 13. Capital measures During 2014, PAION conducted several capital increases. In total, these resulted in gross proceeds amounting to EUR 61.43 million. <pre> Type of capital Date Gross issue proceeds Issue Number of measure (EUR million) shares issued price (EUR) Private 22 July 4.00* 3.1463 1,271,334 placement 2014 Rights offering 9 July 2014 46.26 2.50 18,505,305 Private 17 February 3.17 2.4553 1,290,178 placement 2014 Private 22 January 3.00 2.4079 1,245,899 placement 2014 Rights offering 13 January 5.00 1.80 2,777,777 2014 Total 61.43 25,090,493 </pre> * EUR 0.4 million of the gross proceeds are disclosed as revenues in the context of the license grant. Guidance Development and Commercialization Activities PAION's major goals for 2015 are the start and the conduct of the Phase III development programs with Remimazolam in the US and the EU, the production development for Remimazolam, in particular the validation of the production in market scale, as well as intensifying its pre-marketing and market access activities. Moreover, PAION expects the development activities of its cooperation partners Yichang Humanwell, Hana Pharm, R-Pharm, Pendopharm (all Remimazolam) and Acorda (GGF2) to continue. PAION benefits from the progress of the development of Remimazolam in the form of additional development data as well as in the form of milestone payments and royalties from launch onwards. Partnering discussions for the US and the EU are being held, but options for an independent commercialization are being evaluated as well. For all other regions, including Japan, license or distribution partnerships shall be established in the future, whereby these partnerships shall ideally be based on Phase III results and thus potentially better licensing conditions. The start of the Phase III colonoscopy study in the US is planned for end of March 2015. The completion of patient recruitment is expected before end of 2015. The preparations for the second pivotal Phase III study in the US with bronchoscopy patients are also going according to plan with an expected study start in the second quarter of 2015. Conditional on successful results of these further clinical trials and dependent on interactions with the agency, PAION expects filing with the FDA in 2016. PAION expects that the changes in the reimbursement policy of the "Centers for Medicare & Medicaid Services (CMS)" in the US announced for the beginning of this year will have a positive impact on the Remimazolam business case. Starting 1 January 2015, there is only one reimbursement code for colonoscopies with the aim to save costs for the US healthcare system. The anesthetist and the gastroenterologist can no longer claim those costs separately and it is expected that the total amount will be reduced. Hence, the gastroenterologist will possibly be even stronger incentivized to use sedatives that do not require the presence of an anesthesiologist. In a survey conducted during the New York Society for Gastrointestinal Endoscopy (NYSGE) Congress, 75 % of the surveyed gastroenterologists would be willing to change their current sedation practice if a new drug with the same efficacy as Propofol were available that does not require the presence of an anesthesiologist. For the EU, PAION expects the study start of the Phase III program towards the end of the first half of 2015. Dependent on interactions with the agencies as well as conditional on successful study results, filing for Remimazolam in general anesthesia is expected in early 2017. For Japan, PAION is currently evaluating an alternative strategy for filing with Remimazolam in the indication general anesthesia either by PAION or another partner. Several firms have indicated their interest in a license for Remimazolam. First of all, the completion of the licensing discussions depends on a conclusion of the necessary know-how transfer with Ono. In addition, a strategic decision about the future production of Remimazolam for Japan needs to be made since Ono is no longer available as a producer. This process will be completed in the second half of 2015 at the earliest. PAION wants to evolve into a specialty pharma company with a focus on anesthesia products. In this context, PAION seeks to retain certain marketing rights for Remimazolam for the EU and the US market in order to market Remimazolam itself or together with a partner. In the case of a successful out-licensing by way of a development cooperation, PAION would expect to receive substantial payments. These would be as upfront payments or through sharing of development costs, development milestone payments, and royalties from market approval onwards. In case of a pure marketing cooperation after registration, PAION would expect to receive a comparably higher upfront payment and higher royalties. For this reason, it could also be reasonable and attractive to launch without a partner. Financial Forecast PAION currently concentrates on the development of Remimazolam and does not expect revenues in 2015. Due to the investments in the development of Remimazolam, research and development expenses will be higher than in 2014 and amount to approximately EUR 25 million to EUR 30 million, depending on the progress of development. As a result of these higher research and development expenses, increased tax credits from the British tax authorities in the amount of approximately EUR 5 million to EUR 6 million are expected. The general administrative and selling expenses will increase compared to the prior year particularly due to higher selling expenses, and amount to approximately EUR 4.5 million to EUR 5 million. Accordingly, the net loss will increase significantly compared to prior year and amount to approximately EUR 25 million to EUR 29 million. Key assumptions for the expected developments are the start of the Phase III program in the US end of March 2015 and the beginning of the EU Phase III program towards the end of H1 2015 as well as the scheduled progress of the studies and the development activities. Otherwise, essential parts of the costs would be shifted to 2016. Moreover, the amount of expected expenses is based on the current status of discussions with the regulatory agencies. In the case of additional requirements from the agencies, costs could be incurred in higher amounts than planned. As of 31 December 2014, the PAION Group had cash and cash equivalents of EUR 58.9 million. This is sufficient cash at hand to conduct the planned Phase III programs with Remimazolam including the filing process in the EU and US, and to intensify pre-marketing and market access activities. Moreover, PAION expects additional milestone payments from existing partnerships upon successful development or filing and market approval of Remimazolam in the subsequent years. These milestone payments and future upfront fees and cost reimbursements would strengthen the financial situation but could also be completely or partly used for financing the corporate development. ### Key consolidated financial figures, IFRS <pre> (all figures in KEUR unless otherwise noted) 2014 2013 Revenues 3,456 4,228 Research and development expenses -11,799 -4,584 General administrative and selling expenses -3,702 -3,314 Net result for the period -9,105 -2,212 Earnings per share in EUR for the period (basic) -0.23 -0.09 Earnings per share in EUR for the period (diluted) -0.23 -0.09 Cash flows from operating activities -12,044 -1,746 Cash flows from investing activities -26 -5 Cash flows from financing activities 57,618 -7,163 Intangible assets 3,440 3,494 Cash and cash equivalents 58,912 13,292 Equity 62,607 13,329 Non-current liabilities 17 28 Current liabilities 3,924 4,659 Balance sheet total 66,548 18,016 Number of group employees (year end) 21 13 </pre> The full annual financial report will be available as from 18 March 2015 on our corporate website at http://www.paion.com/en/berichte-2015. Conference call and webcast In addition to the publication of the results, the Management Board of PAION will host a public conference call (conducted in English) on 18 March 2015 at 2 p.m. CET (1 p.m. GMT, 9 a.m. EDT) to present the financial results of 2014, highlight the most important events and provide a pipeline and strategy update and financial outlook. To access the English call starting at 2 p.m., participants may dial from * Germany +49 (0) 69 7104 45598, * UK +44 (0) 20 3003 2666 and * US +1 212 999 6659 * Other countries: please use the UK number When prompted, you will be asked to give the password "PAION". The conference call will be supplemented by a webcast presentation which can be accessed during the call under the following link: www.meetingzone.com/presenter?partCEC=2214205. About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anesthesia products. Remimazolam is intended to be the basis for its future marketing activities. Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------- 18.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 334199 18.03.2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 134

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Calumet Sets 2025 Plans for Investor Engagement Events

Updated Category News Views 381

Calumet Announces Participation in Upcoming Investor Conferences Calumet, Inc. (NASDAQ: CLMT) is gearing up to make an important presence at two significant investor conferences scheduled for January 2025. The event will offer Calumet a platform to connect with investors and discuss the company's innovative strategies. Goldman Sachs Energy Conference The first conference...

Continue Reading
PACS Group Investors Face Class Action for Alleged Fraud

Updated Category News Views 336

PACS Group Investors Face Class Action for Alleged Fraud In recent developments, a significant class action lawsuit has been initiated against PACS Group, Inc., a recognized leader in the skilled nursing facility sector. The lawsuit, spearheaded by a prestigious law firm, is rooted in serious allegations of securities fraud involving the company and several of its senior...

Continue Reading
Discover the Magic: MINISO Unveils Harry Potter Collection

Updated Category News Views 710

Introducing a Magical Collection from MINISO MINISO, a renowned lifestyle brand celebrated for its affordable quality products, has launched an enchanting array of over 800 Harry Potter-inspired items. This exciting collection will be available in MINISO stores globally, captivating fans of the beloved franchise with affordable yet stylish merchandise that embodies the...

Continue Reading
Westwood Launches Enhanced Income Opportunity ETF for Growth

Updated Category News Views 95

Westwood Launches Enhanced Income Opportunity ETF Westwood Holdings Group, recognized as a leading boutique asset manager, is delighted to announce the creation of the Westwood Enhanced Income Opportunity ETF, also referred to as YLDW. This innovative investment option is a fresh addition to the company’s Enhanced Income Series™ ETFs, which has significantly expanded...

Continue Reading
Upcoming Earnings Announcement: Canadian Pacific Kansas City

Updated Category News Views 161

Canadian Pacific Kansas City to Announce Q2 Earnings Canadian Pacific Kansas City (TSX: CP) has announced its plans to release its financial and operational results for the second quarter of 2025 after market closure. This highly anticipated announcement will take place, giving stakeholders insight into the company's performance and strategic direction. Conference Call...

Continue Reading